Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Subscribe To Our Newsletter & Stay Updated
